Edition:
India

Concert Pharma Reports Positive Results From Early-Stage Studies Testing Its Experimental Schizophrenia Treatment


Wednesday, 12 Jun 2019 

June 12 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM PHASE 1 STUDIES EVALUATING CTP-692 IN HEALTHY VOLUNTEERS.CONCERT PHARMACEUTICALS INC - EXPECTS TO INITIATE A PHASE 2 TRIAL IN PATIENTS WITH SCHIZOPHRENIA IN Q4 OF 2019.CONCERT PHARMA - SAFETY ASSESSMENTS IN SINGLE- & MULTIPLE-ASCENDING DOSE TRIALS IN HEALTHY VOLUNTEERS SHOWED DRUG WAS WELL TOLERATED OVER DOSE RANGES TESTED.CONCERT PHARMACEUTICALS - STUDY SHOWED KEY BLOOD AND URINE MARKERS OF KIDNEY FUNCTION DID NOT INDICATE ANY SIGNS OF RENAL IMPAIRMENT. 

Company Quote

10.8
 --
20 Sep 2019